Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage

Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and have consistently replaced the previous dominant variant. Therapeutics against variants of SARS-CoV-2 are urgently needed. Ide...

Full description

Bibliographic Details
Main Authors: Wen Jiang, Zherui Zhang, Yuhe Zhu, Ben Chen, Chunying Gu, Zhiyan Liu, Xukai Zhang, Hualong Xiong, Yanan Zhang, Bin Zheng, Rongjuan Wang, Shasha Jiao, An Wang, Tianying Zhang, Jinchao Zhang, Shuang Wang, Bo Zhang, Gang Li, Xun Gui
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
SARS-CoV-2
neutralizing antibody
escape mutation
antibody therapeutics
safety profile
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.926750/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.926750/full

Similar Items